WO2016116075A1 - Method of isolation of a mixture of enantiomers of 1-(6-bromo-2-methoxyquinolin-3-yl)-4-(dimethylamino)-2-(naphthalen-1-yl)-1-phenylbutan-2-ol - Google Patents

Method of isolation of a mixture of enantiomers of 1-(6-bromo-2-methoxyquinolin-3-yl)-4-(dimethylamino)-2-(naphthalen-1-yl)-1-phenylbutan-2-ol Download PDF

Info

Publication number
WO2016116075A1
WO2016116075A1 PCT/CZ2016/000005 CZ2016000005W WO2016116075A1 WO 2016116075 A1 WO2016116075 A1 WO 2016116075A1 CZ 2016000005 W CZ2016000005 W CZ 2016000005W WO 2016116075 A1 WO2016116075 A1 WO 2016116075A1
Authority
WO
WIPO (PCT)
Prior art keywords
mixture
acid
enantiomers
bromo
isomers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CZ2016/000005
Other languages
French (fr)
Inventor
Petr Lustig
Martin STEFKO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zentiva KS
Original Assignee
Zentiva KS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentiva KS filed Critical Zentiva KS
Publication of WO2016116075A1 publication Critical patent/WO2016116075A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B57/00—Separation of optically-active compounds

Definitions

  • the (1S,2S); (1R,2R); (1S,2R) and (1R,2S) isomers of l-(6-bromo-2-methoxyquinolin-3-yl)-4- (dimethylamino)-2- (naphthalen- l-yl)-l-phenylbutan-2-ol can be distinguished.
  • this mixture can be referred to as a mixture of two racemates having different physical properties.
  • an E I racemic mixture of the (1R,2S) and (1S,2R) enantiomers which can be referred to as El and E2
  • an E II racemic mixture of the (1R,2R) and (1S,2S) enantiomers E3 and E4 will be used hereinafter throughout the description of the invention.
  • the basic patent WO 2004/011436 has mentioned the enantiomer, ( S,pR)-6-bromo-a-[2- (dimemylamino)ethyl]-2-methoxy-a-l-naphthalenyl-p-phenyl-3-quinoline ethanol (El), as a substance used for the treatment of mycobacterial disorders, especially for the treatment of disorders caused by the pathogenic mycobacteria Mycobacterium (M. ) tuberculosis, M. bovis, M. avium and M. marinum.
  • the mixture of four optical isomers is prepared using the same method as mentioned in the basic patent.
  • the obtained reaction mixture consists of two racemic mixtures.
  • the process of this separation comprises a reaction of a mixture containing the stereoisomers of (6-bromo-2-memoxyquinolm-3-yl)-4-(dim
  • the inoculation with this salt can be done both before and after addition of the chiral compound of 4-hychoxydmaphtho[2 ; l-d: ,2'-f][l ⁇ 3,2]dioxaphosphepine 4-oxide.
  • the chiral compound of 4-hydroxydinaphtho[2,l-d: ,2'-f][l,3,2]dioxaphosphepine 4-oxide is added to the mixture of stereoisomers of (6-bromo-2-methoxyquinolin-3-yl)-4- (dimemylanoino)-2-(naphthalen-l-yl)-l-phenylbutan-2-ol in the form of a solution in a dipolar aprotic solvent, best in dimethyl sulfoxide.
  • the document also deals with a process of isolation of (aS,pR)-6-bromo-a-[2- (dimethy lamino)ethy l]-2-methoxy-a- 1 -naphthaleny 1- ⁇ -pheny 1- 3 -quino line ethanol (El), wherein the starting mixture of the four stereoisomers of 6-bromo-a-[2- (dimemylamino)emyl]-2-memoxy-a-l-naphthaIenyl-p-phenyl-3-quinoline ethanol is prepared by reaction of 3-benzyl-6-bromo-2-methoxyquinoline and (3-dimethylamino)-r- propionaphthone in the presence of lithium diisopropylamide at a temperature of from -70°C to -80°C in tetrahydrofuran.
  • a suitable acid is added to the reaction mixture, e.g. acetic acid, at a reduced temperature (less than 0 °C).
  • the (aR,pS) stereoisomer is isolated from the mixture of the stereoisomers with the use of the chiral compound 4-hydroxydmaphmo[2,l-d: ,2'-fJ[l s 3 ⁇ 2]dioxaphosphepine 4- oxide or its derivatives (procedure, see the first section of the document).
  • reaction mixture to which a suitable acid (e.g. acetic acid) has been added, is used as the starting mixture of this enrichment step.
  • a suitable acid e.g. acetic acid
  • the invention provides a method of isolation of the mixture E I of enantiomers of (1R,2S)-1- (6-bromo-2-memoxyquinolm-3-yl)-4-(cUmemylam
  • the racemate of El and E2 obtained this way is converted to salts with an organic or inorganic acid.
  • the following acids can be used for such conversion: hydrochloric, hydrobromic, sulphuric, phosphoric, L-tartaric, DL-tartaric, D-tartaric, citric or oxalic acids.
  • these salts are converted back to the El and E2 bases by treatment with an inorganic base.
  • a mixture containing the four optical isomers is prepared, the synthesis being carried out in the same way as described in the basic patent WO 2004/011436, or EP 1888604 Bl, by reaction of 3-benzyl-6-bromo-2-memoxyquinoline and (3-dimethylamino)-l'- propionaphthone in the presence of lithium diisopropylarnide at a temperature of -60°C to -80° C in a solvent selected from cyclic ethers, best in tetrahydrofuran.
  • the isolation of the enantiomeric mixture of compounds El and E2 (E I) in the basic form from the mixture of the four optical isomers is carried out by removing of the enantiomeric pair of the E3 and E4 compounds (E II) by crystallization in a suitable solvent.
  • the resulting precipitate of E II is separated by filtration, while a mixture of the El and E2 enantiomers remains in the mother liquor, their contents being significantly higher than the contents of the E3 and E4 enantiomers.
  • suitable solvent refers to such a solvent that enables separation of at least one crystal of the desired solid phase; i.e. of the mixture of E3 and E4 in the first step, of El and E2 after concentration of the mother liquors in the second step and, finally, El and E2 of a higher purity in the third step.
  • the mixture of the four optical isomers El, E2, E3 and E4 is prepared by a reaction of 3- benzyl-6-bromo-2-methoxyquinoline and (3-dimethylamino)- -propionaphthone in the presence of lithium diisopropylamide at a temperature of -60°C to -80°C in a solvent selected from cyclic ethers, best in tetrahydrofuran.
  • This organic layer is partly concentrated and crystallized at the room temperature to provide a precipitate containing the enantiomeric mixture E II in a high content relative to the content of the enantiomeric mixture E I.
  • the content of the enantiomeric mixture E I varies in the range of 5-20%.
  • the content of the enantiomeric mixture E I is determined using the liquid chromatography method.
  • the resulting mixture E II is separated by filtration and the mother liquor is further concentrated. Crystallization at a temperature of 5 to 10°C provides a second fraction of the enantiomeric mixture E II. This is removed by filtration and the mother liquor contains the enantiomeric mixture E I in a high content relative to the content of the enantiomeric mixture E II.
  • the content of the enantiomeric mixture E II varies in the range of 5-25%.
  • the content of the enantiomeric mixture E II is determined using the liquid chromatography method.
  • the mother liquor, enriched in the enantiomeric mixture E I, is concentrated and a suitable solvent is added.
  • the solvent can be a C ⁇ to C 4 alcohol, an ester, a dipolar aprotic one, or a cyclic ether.
  • the most suitable ones are methan-l-ol, isopropyl acetate, acetonitrile, or 2- methyltelxahydrofuran.
  • the mother liquor obtained by removal of the precipitated enantiomeric mixture E II by filtration can also be processed in the following way.
  • This invention also relates to a method of isolation of the enantiomeric mixture E I (El, E2) in a high chemical and optical purity by means of formation of salts of the individual optical isomers.
  • This organic layer is concentrated and crystallized at the room temperature to result in precipitation of the enantiomeric mixture E II, which is separated by filtration.
  • the mother liquor contains a solution of the enantiomers E I in a solvent used as the reaction environment, selected from cyclic ethers, best in 2-memyltetrahydrofuran or tetrahydrofuran.
  • the content of the enantiomeric mixture E II in the obtained mother liquor usually varies in the range of 5 to 25%.
  • the contents of compounds are determined using the liquid chromatography method.
  • a suitable organic solvent is ethanol, acetomtrile, tetrahydrofuran, or 2-memyltetrahydrofuran.
  • a salt prepared this way contains a very low amount of the salts of enantiomers E II, usually less than 1%.
  • Re-crystallization of the salt of enantiomers E I in a suitable solvent provides a product with a content of the enantiomeric mixture E II lower than 0.15%.
  • a suitable solvent examples include a Ci to C alcohol, isopropyl acetate, ethyl methyl ketone, tetrahydrofuran, or 2-methyltetrahydrofuran.
  • a suitable solvent examples include a Ci to C alcohol, isopropyl acetate, ethyl methyl ketone, tetrahydrofuran, or 2-methyltetrahydrofuran.
  • the content of enantiomers E II in the crystallized compound is determined using the liquid chromatography method.
  • the base is released from the salt of the El and E2 enantiomers by extraction with a suitable organic solvent and an aqueous solution of an inorganic base.
  • the base of the enantiomeric mixture E I purified this way can be used for the preparation of (1R,2S) bedaquiline in a quality complying with pharmaceutical purposes.
  • the optical isomer (1R,2S) of bedaquiline separates as a solid substance after crystallization of the enantiomer E I with a suitable chiral acid in a suitable solvent. Re-crystallization in a suitable solvent provides the product in an acceptable chemical and optical purity.
  • alcohols, cyclic ethers and dipolar aprotic solvents and their mixtures can be selected.
  • the organic layer obtained by the process in accordance with (A) is partly concentrated and the mixture is left to crystallize at the room temperature for 17 hours and the precipitate is aspirated and washed with 2-methyltetrahydrofuran.
  • a solid substance is obtained containing 80% of the E3+E4 enantiomers and 0.5% of the E1+E2 enantiomers.
  • the mother liquor is further concentrated and left to crystallize at 5 to 10°C. A precipitate results, which is removed by aspiration.
  • a solid substance is obtained with the composition of 76% of the E3+E4 enantiomers and 5% of the E1+E2 enantiomers
  • a product is obtained with the composition of 7% of the E3+E4 enantiomers and 85% of the E1+E2 enantiomers.
  • the organic layer obtained by the process in accordance with (A) is concentrated, acetonitrile (100 ml) is added and the mixture is brought to boil. A solid substance suspension is formed, which is aspirated in the hot state.
  • a product is obtained with the composition of 6% of the E3+E4 enantiomers and 82% of the E1+E2 enantiomers.
  • a product is obtained with the composition of 17% of the E3+E4 enantiomers and 71% of the E1+E2 enantiomers.
  • the organic layer obtained by the process in accordance with (A) is used for the preparation of the salts of the enantiomers.
  • the product enriched in the El and E2 enantiomers is used for the preparation of the salts.
  • the enriched product is dissolved in tetrahydrofuran at a temperature of 40-50°C. After cooling to 30°C a solution of an acid is added. The resulting precipitate is stirred at the room temperature for 2-3 hours. The precipitate is aspirated, washed and dried.
  • the mixture is cooled to a temperature lower than 0°C.
  • HPLC 95% content of the El + E2 enantiomers, 0.8% content of the E3 + E4 enantiomers.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A method of isolation of the E1 and E2 optical isomers, forming an enantiomeric mixture, from a mixture of four optical isomers E1, E2, E3, E4, wherein the enantiomeric mixture of E3 and E4 is first separated from the solution and subsequently the mixture of E1 and E2 is isolated in the form of a base in the mother liquors, wherein E1 is (1R,2S)-1-(6-bromo-2-memoxyqumolm-3-yl)-4-(dimethylamino)-2- (naphthalen-1-yl)-1-phenylbutan-2-ol, E2 is the (1S,2R)-enantiomer of the same compound, and E3 and E4 are the (1R,2R) and (1S,2S) enantiomers, respectively.

Description

METHOD OF ISOLATION OF A M IXTURE OF ENANTIOMERS OF
-(6-BROMO-2-METHOXYQUINOLIN-3-YL)-4-(DI METHYLAM INO)-2-(NAPHTHALEN-1 -YL)-1 -PHENYLBUTAN-2-OL
Technical Field
A method of isolation of the El and E2 optical isomers forming an enantiomeric mixture, from a mixture of four optical isomers El, E2, E3, E4, wherein an enantiomeric mixture of E3 and E4 is first separated from said mixture and subsequently a mixture of El and E2 is isolated in the form of a base in mother liquors.
Background Art
1 -(6-Bromo-2-memoxyqumolin- 3-yl)-4-(dimethylamino)-2- (naphthalen- 1 -yl)- 1 -phenylbutan- 2-ol of formula I
Figure imgf000002_0001
is a substance with two optical centres, having four optical isomers. Thus, the (1S,2S); (1R,2R); (1S,2R) and (1R,2S) isomers of l-(6-bromo-2-methoxyquinolin-3-yl)-4- (dimethylamino)-2- (naphthalen- l-yl)-l-phenylbutan-2-ol can be distinguished.
From another point of view this mixture can be referred to as a mixture of two racemates having different physical properties. Thus, one can define an E I racemic mixture of the (1R,2S) and (1S,2R) enantiomers, which can be referred to as El and E2, as well as an E II racemic mixture of the (1R,2R) and (1S,2S) enantiomers E3 and E4. These identifications will be used hereinafter throughout the description of the invention. The basic patent WO 2004/011436 has mentioned the enantiomer, ( S,pR)-6-bromo-a-[2- (dimemylamino)ethyl]-2-methoxy-a-l-naphthalenyl-p-phenyl-3-quinoline ethanol (El), as a substance used for the treatment of mycobacterial disorders, especially for the treatment of disorders caused by the pathogenic mycobacteria Mycobacterium (M. ) tuberculosis, M. bovis, M. avium and M. marinum.
In the basic patent WO 2004/011436, the isolation of the El enantiomer from the diastereoisomeric mixture EI is carried out by means of chiral chromatography.
In the first section of the description of the invention in the process patent EP 1888604 Bl, the isolation of the optical isomers is carried out by crystallization, which is a more advantageous method for the preparation of (aS, R)-6-bromo-a-[2-(dimethylamino)ethyl]-2- methoxy-a-1- naphthalenyl- -phenyl-3-quiiioline ethanol (El) in a larger production scale as compared to the chiral chromato raphy method.
The mixture of four optical isomers is prepared using the same method as mentioned in the basic patent. The obtained reaction mixture consists of two racemic mixtures.
Isolation of El from the mixture of optical mixture is carried out, in the patent EP 1888604 Bl, by separation with the chiral compound of 4-hydxoxydinaphtho[2,l-d. ,2'- f][l,3,2]dioxaphosphepine 4-oxide or its derivatives.
The process of this separation comprises a reaction of a mixture containing the stereoisomers of (6-bromo-2-memoxyquinolm-3-yl)-4-(dim
2-ol with the above mentioned chiral separating agent in a suitable solvent. This is followed by separation of the precipitated salt and its re-crystallization, or stirring in a suitable solvent. Finally, the base of (6-bromo-2-memoxyqumolm-3-yl)-4-(dimemylammo)-2-(naphthalen-l- yl)-l-phenylbutan-2-ol is released from this salt.
Out of the many derivatives of the chiral compound of 4-hydroxydinaphtho[2,l-d: ,2'- f][l,3,2]dioxaphosphepine 4-oxide, (llbR)-4-hydroxydinaphtho[25l-d: ,2'- f][l,3,2]dioxaphosphepine 4-oxide is mentioned as the most advantageous one.
As the most suitable solvent for separation of (aS, R)-6-bromo-a-[2-(dimethylamino)ethyl]-2- memoxy-o^l-naphthalenyl-p-phenyl-3-qumoline ethanol from the mixture of optical isomers, a mixture of acetone and dimethyl sulfoxide is mentioned. One molar equivalent of the derivative of 4-hydroxydinaphtho[2,l-d:l';2'- fJ[l,3;2]dioxaphosphepine 4-oxide is mentioned in the patent as the most suitable quamountantity for separation of the stereoisomer (aS,pR)-6-bromo-a-[2- (dimemylamino)ethyl]-2- methoxy-a-1 -naphthalenyl- -phenyl-3-quinoline ethanol.
For good separation of the salt, the patent mentions inoculation of the reaction mixture with a mixture with the salt of (aS^R)-6-bromo-a-[2-(dimethylamino)ethyl]-2-methoxy-a-l- naphthalenyl- -phenyl-3-quinoline ethanol* (11 bR)-4-hydroxydinaphtho[2, 1 -d: 1 ',2 '- f][l,3,2]dioxaphosphepine 4-oxide.
The inoculation with this salt can be done both before and after addition of the chiral compound of 4-hychoxydmaphtho[2;l-d: ,2'-f][l}3,2]dioxaphosphepine 4-oxide.
The chiral compound of 4-hydroxydinaphtho[2,l-d: ,2'-f][l,3,2]dioxaphosphepine 4-oxide is added to the mixture of stereoisomers of (6-bromo-2-methoxyquinolin-3-yl)-4- (dimemylanoino)-2-(naphthalen-l-yl)-l-phenylbutan-2-ol in the form of a solution in a dipolar aprotic solvent, best in dimethyl sulfoxide.
An improvement of the optical and chemical quality by means of the salt of ( S,pR)-6-bromo- -[2-(dimethylammo)emyl]-2-memoxy-a-l-naphmalenyl-P-phenyl-3-quinoline ethanol*4- hydroxydmaphtho[2,l-d: s2'-f][l,3,2]dioxaphosphepine 4-oxide is achieved through its re- crystallization or stirring as a suspension, namely in acetone, Ν,Ν-dimethyl formamide, or a mixture of N,N-dimethyl formamide with water or an alcohol, dimethyl sulfoxide, or its mixture with water or an alcohol. Acetone is the most suitable one of the above mentioned solvents or their mixtures.
The release of the base of (6-bromo-2-memoxyquinolin-3-yl)-4-(dimemylamino)-2- (naphthalen-l-yl)-l-phenylbutart-2-ol from the salt with 4-hydroxydinaphtho[2,l-d:l ',2'- fJ[l,3,2]dioxaphosphepine 4-oxide is achieved, according to the process patent, by means of reaction of the salt with a suitable base in a suitable organic solvent. Toluene or tetiahydrofuran can be used as the organic solvent, toluene being more suitable. Suitable bases are carbonates (sodium or potassium), hydrogen carbonates (sodium or potassium), sodium phosphate and hydrogen phosphate. Potassium carbonate is mentioned as more suitable.
Increasing of the purity of the base of (aS, R)-6-bromo-a-[2-(dimethylamino)ethyl]-2- methoxy-a-l-naphthalenyl- -phenyl-3-quinoline ethanol can be achieved by crystallizing the same from a suitable solvent, e.g. from toluene or ethanol. The second section of the invention description mentions an alternative isolation of El by separation after the reaction with (llbS)-4-hydroxydinaphtho[2,l-d: ,2'- f][l,3,2]dioxaphosphepine 4-oxide. El is obtained from the mother liquor after separation of the resulting precipitate of the E2 stereoisomer. The alternative isolation process is analogous to the process mentioned in the first section of the description of the invention.
The document also deals with a process of isolation of (aS,pR)-6-bromo-a-[2- (dimethy lamino)ethy l]-2-methoxy-a- 1 -naphthaleny 1- β-pheny 1- 3 -quino line ethanol (El), wherein the starting mixture of the four stereoisomers of 6-bromo-a-[2- (dimemylamino)emyl]-2-memoxy-a-l-naphthaIenyl-p-phenyl-3-quinoline ethanol is prepared by reaction of 3-benzyl-6-bromo-2-methoxyquinoline and (3-dimethylamino)-r- propionaphthone in the presence of lithium diisopropylamide at a temperature of from -70°C to -80°C in tetrahydrofuran.
A suitable acid is added to the reaction mixture, e.g. acetic acid, at a reduced temperature (less than 0 °C). The (aR,pS) stereoisomer is isolated from the mixture of the stereoisomers with the use of the chiral compound 4-hydroxydmaphmo[2,l-d: ,2'-fJ[ls3}2]dioxaphosphepine 4- oxide or its derivatives (procedure, see the first section of the document).
In the said process, an enrichment of the mixture was also used, which means increasing of the content of the racemic mixture of (aS^Ry6-bromo-a-[2-(dimethylamino)ethyl]-2-methoxy-a- 1 -naphthaleny Ι-β-phenyl- 3 -quinoline ethanol and (aR,pS)-6-bromo-a-[2-
(dimethylamino)ethy l]-2-methoxy-a- 1 -naphthalenyl- -phenyl-3-quinoline ethanol by removing the racemic mixture of (aR, R)-6-bromo-a-[2-(dimethylamino)ethyl]-2-methoxy-a- l-naphthalenyl- -phenyl-3-quinoline ethanol and (aS,pS)-6-bromo-a-[2-
(dimethylamino)ethyl]-2-methoxy-a- 1 -naphthalenyl- p-phenyl-3 -quinoline ethanol .
The reaction mixture, to which a suitable acid (e.g. acetic acid) has been added, is used as the starting mixture of this enrichment step.
Disclosure of Invention
The invention provides a method of isolation of the mixture E I of enantiomers of (1R,2S)-1- (6-bromo-2-memoxyquinolm-3-yl)-4-(cUmemylam
ol (El) and (lS,2R)-l-(6-bromo-2-memoxyqumolm-3-yl)-4-(dimethylammo)-2-(naphthalen- l-yl)-l-phenyibutan-2-ol (E2) from a mixture of E I and E II, i.e. of the four optical isomers (El, E2, E3 and E4), consisting of first separating the E3 and E4 enantiomers from said mixture, followed by further processing of the mother liquors so that the El and E2 enantiomers can be isolated therefrom.
In a preferred embodiment, the racemate of El and E2 obtained this way is converted to salts with an organic or inorganic acid. The following acids can be used for such conversion: hydrochloric, hydrobromic, sulphuric, phosphoric, L-tartaric, DL-tartaric, D-tartaric, citric or oxalic acids. After purification, these salts are converted back to the El and E2 bases by treatment with an inorganic base.
Detailed description of the invention
A mixture containing the four optical isomers is prepared, the synthesis being carried out in the same way as described in the basic patent WO 2004/011436, or EP 1888604 Bl, by reaction of 3-benzyl-6-bromo-2-memoxyquinoline and (3-dimethylamino)-l'- propionaphthone in the presence of lithium diisopropylarnide at a temperature of -60°C to -80° C in a solvent selected from cyclic ethers, best in tetrahydrofuran.
The isolation of the enantiomeric mixture of compounds El and E2 (E I) in the basic form from the mixture of the four optical isomers is carried out by removing of the enantiomeric pair of the E3 and E4 compounds (E II) by crystallization in a suitable solvent. The resulting precipitate of E II is separated by filtration, while a mixture of the El and E2 enantiomers remains in the mother liquor, their contents being significantly higher than the contents of the E3 and E4 enantiomers.
Further enrichment of the contents of the El and E2 enantiomers in relation to the contents of the E3 and E4 enantiomers is carried out after concentration of the mother liquor by crystallization in a suitable content In this manner, it is possible to obtain a product in the basic form, which contains a mixture of the E3 and E4 enantiomers, the contents of these enantiomers being lower than 3%. The chemical and optical purity of the product obtained this way can be increased by its re-crystallization from a suitable solvent. In this description of the invention the term suitable solvent refers to such a solvent that enables separation of at least one crystal of the desired solid phase; i.e. of the mixture of E3 and E4 in the first step, of El and E2 after concentration of the mother liquors in the second step and, finally, El and E2 of a higher purity in the third step.
The mixture of the four optical isomers El, E2, E3 and E4 is prepared by a reaction of 3- benzyl-6-bromo-2-methoxyquinoline and (3-dimethylamino)- -propionaphthone in the presence of lithium diisopropylamide at a temperature of -60°C to -80°C in a solvent selected from cyclic ethers, best in tetrahydrofuran. After addition of water to the reaction mixture, an organic layer separates, which contains four optical isomers, (lR,2S)-l-(6-bromo-2- methoxyquinolin-3 -yl)-4-(dimethylamino)-2-(naphthalen- 1 -yl)- 1 -phenylbutan-2-ol (El ), (IS ,2R)- 1 -(6-bromo -2-methoxyquinolin-3 -yl)-4-(dimemylamino)-2-(naphthalen- 1 -yl)- 1 - phenylbutan-2-ol (E2), (1R,2R)- l-(6-bromo-2-memoxyqumolm-3-yl)-4-(dimemylairiino)-2- (naphthalen-l-yl)-l-phenylbutan-2-ol (E3) and (lS^S)-l-(6-bromo-2-methoxyquinolin-3-yl)- 4-(dime1 lammo)-2-(naphthalen-l-yl)-l-phenylbutan-2-ol (E4).
This organic layer is partly concentrated and crystallized at the room temperature to provide a precipitate containing the enantiomeric mixture E II in a high content relative to the content of the enantiomeric mixture E I. The content of the enantiomeric mixture E I varies in the range of 5-20%. The content of the enantiomeric mixture E I is determined using the liquid chromatography method.
The resulting mixture E II is separated by filtration and the mother liquor is further concentrated. Crystallization at a temperature of 5 to 10°C provides a second fraction of the enantiomeric mixture E II. This is removed by filtration and the mother liquor contains the enantiomeric mixture E I in a high content relative to the content of the enantiomeric mixture E II. The content of the enantiomeric mixture E II varies in the range of 5-25%. The content of the enantiomeric mixture E II is determined using the liquid chromatography method.
The mother liquor, enriched in the enantiomeric mixture E I, is concentrated and a suitable solvent is added.
The solvent can be a C\ to C4 alcohol, an ester, a dipolar aprotic one, or a cyclic ether.
The most suitable ones are methan-l-ol, isopropyl acetate, acetonitrile, or 2- methyltelxahydrofuran.
By addition of the solvent, a precipitate results, which is removed by filtration. A product with a low content of the enantiomeric mixture E II is obtained and, at the same time, the chemical quality of said product is increased as this process removes some side products of the reaction and substantially reduces the contents of some of them. The chemical purity can be further increased by re-crystallization of the crude isolate. For the recrystaUization, alcohols, esters and cyclic ethers and their mixtures can be selected. Suitable solvents are propan-l-ol, propan-
2- ol, ethyl acetate, isopropyl acetate, 2-methyltetrahydrofuran.
The mother liquor obtained by removal of the precipitated enantiomeric mixture E II by filtration can also be processed in the following way.
This invention also relates to a method of isolation of the enantiomeric mixture E I (El, E2) in a high chemical and optical purity by means of formation of salts of the individual optical isomers.
A mixture of all the four optical isomers El, E2, E3 and E4 is again prepared by a reaction of
3- benzyl-6-bromo-2-methoxyquinoline and (3-dimemylamino)- -propionaphthone in the presence of lithium diisopropylamide at a temperature of -60°C to -80° C in a solvent selected from cyclic ethers, best in tetrahydrofuran. After addition of water to the reaction mixture, an organic layer separates, which contains the four above mentioned optical isomers.
This organic layer is concentrated and crystallized at the room temperature to result in precipitation of the enantiomeric mixture E II, which is separated by filtration.
The mother liquor contains a solution of the enantiomers E I in a solvent used as the reaction environment, selected from cyclic ethers, best in 2-memyltetrahydrofuran or tetrahydrofuran. The content of the enantiomeric mixture E II in the obtained mother liquor usually varies in the range of 5 to 25%. The contents of compounds are determined using the liquid chromatography method.
An inorganic or organic acid dissolved in water or in a suitable organic solvent is added to this solution of enantiomers E I. A suitable organic solvent is ethanol, acetomtrile, tetrahydrofuran, or 2-memyltetrahydrofuran.
To produce salts of the El and E2 enantiomers, hydrochloric acid, sulphuric acid, phosphoric acid, L·tartaric acid, DL-tartaric acid, D-tartaric acid, citric acid and oxalic acid can be used. A salt prepared this way contains a very low amount of the salts of enantiomers E II, usually less than 1%.
Re-crystallization of the salt of enantiomers E I in a suitable solvent provides a product with a content of the enantiomeric mixture E II lower than 0.15%.
Examples of a suitable solvent are a Ci to C alcohol, isopropyl acetate, ethyl methyl ketone, tetrahydrofuran, or 2-methyltetrahydrofuran. The content of enantiomers E II in the crystallized compound is determined using the liquid chromatography method.
The base is released from the salt of the El and E2 enantiomers by extraction with a suitable organic solvent and an aqueous solution of an inorganic base.
For the extraction, e.g., 2-methyltetrahydrofuran or toluene and an aqueous solution of inorganic carbonates or hydrogen carbonates can be used.
2- emylte1rahydrofuran and sodium carbonate appear to be the most suitable.
The base of the enantiomeric mixture E I purified this way can be used for the preparation of (1R,2S) bedaquiline in a quality complying with pharmaceutical purposes. The optical isomer (1R,2S) of bedaquiline separates as a solid substance after crystallization of the enantiomer E I with a suitable chiral acid in a suitable solvent. Re-crystallization in a suitable solvent provides the product in an acceptable chemical and optical purity. For the re-crystalHzation, alcohols, cyclic ethers and dipolar aprotic solvents and their mixtures can be selected.
Experimental part
(A)
Preparation of a mixture of the enantiomers of (6-bromc 2-memoxyquinolin-3-ylV4- f dimethylammo)-2-(naphthalen- 1 -yl 1 -phenylbutan-2-ol
A solution of lithium diisopropylamide (0.05 mol), as a 2-moIar solution in a tetrahydrofuran, heptane, ethylbenzene mixture, is added to tetrahydrofuran (20 ml), cooled down to -50 to -60°C, in an apparatus under an inert atmosphere. The mixture is cooled down to -65 to -75°C and a solution of 3-benzyl-6-bromo-2-methoxyqunoline (0.0314 mol) in tetrahydrofuran (17 ml) is added during 10 to 20 minutes. This mixture is stirred at a temperature of -65 to -70°C for 30 to 60 minutes. Then, a solution of (3-dimethylamino)-l '- propionaphthone (0.0352 mol) in tetrahydrofuran (17 ml) is added during 1 to 30 minutes. The reaction mixture is stirred at a temperature of -65 to -70°C for 30 to 150 minutes. After this time period, water (100 ml) is slowly added to the reaction mixture dropwise. 2- Memyltetrahydrofuran (35 ml) is added to the mixture and the mixture is stirred for 30 minutes. The formed organic layer is separated. More 2-memyltetrahydrofuran (45 ml) is added; the organic layer is shaken with a sodium chloride solution and separated. (B)
Isolation of the enantiomeric mixture of C1R.2S -l-('6-bromo-2-methoxyquinolin-3-yl')-4- fdimethylamino)-2-fnaphthalen-l-yn-l-phenylbutan-2-ol (Ε1Ί and aS.2RVl-f6-bromo-2- memoxyqumolm-3-yl)-4-(Q^emylammo)-2-(naphthalen- 1-yl)- l-phenylbutan-2-ol (Έ2)
(1)
The organic layer obtained by the process in accordance with (A) is partly concentrated and the mixture is left to crystallize at the room temperature for 17 hours and the precipitate is aspirated and washed with 2-methyltetrahydrofuran.
A solid substance is obtained containing 80% of the E3+E4 enantiomers and 0.5% of the E1+E2 enantiomers.
The mother liquor is further concentrated and left to crystallize at 5 to 10°C. A precipitate results, which is removed by aspiration.
A solid substance is obtained with the composition of 76% of the E3+E4 enantiomers and 5% of the E1+E2 enantiomers
The mother liquor is concentrated and isopropyl acetate is added. The resulting precipitate is aspirated and washed with a solvent
A product is obtained with the composition of 7% of the E3+E4 enantiomers and 85% of the E1+E2 enantiomers.
Yield: 6.5 g (37.3 %).
(2)
The organic layer obtained by the process in accordance with (A) is concentrated, acetonitrile (100 ml) is added and the mixture is brought to boil. A solid substance suspension is formed, which is aspirated in the hot state.
The solid substance removed by filtration is washed with acetonitrile and dried. Its composition: 85% of the E3+E4 enantiomers, 1.2% of the E1+E2 enantiomers.
After cooling to the room temperature, a precipitate separates from the mother liquor, which is aspirated and washed with the solvent.
A product is obtained with the composition of 6% of the E3+E4 enantiomers and 82% of the E1+E2 enantiomers.
Yield: 2.1 g (12%). The other mother liquor is concentrated, an ethanol - heptane mixture 1:1 (20 ml) is added and the mixture is stirred at the room temperature. The resulting precipitate is aspirated and washed with the solvent.
A product is obtained with the composition of 17% of the E3+E4 enantiomers and 71% of the E1+E2 enantiomers.
Yield: 0.9 g (5%).
Preparation of salts of the enantiomers (lR,2S -l-f6-bromo-2-methoxyquinolin-3-yl)-4- (dimemylamino -2-f naphthalen- 1 -yl)- 1 -phenylbutan-2-ol (El ) and f 1 S.2R)- 1 -f 6-bromo-2- memoxyquinolin-3-yi)-4-(dimem^
The organic layer obtained by the process in accordance with (A) is used for the preparation of the salts of the enantiomers.
This is processed by the procedure of Bl or B2.
The product enriched in the El and E2 enantiomers is used for the preparation of the salts.
General procedure of preparation of salts of the El and E2 enantiomers
The enriched product is dissolved in tetrahydrofuran at a temperature of 40-50°C. After cooling to 30°C a solution of an acid is added. The resulting precipitate is stirred at the room temperature for 2-3 hours. The precipitate is aspirated, washed and dried.
If no precipitate separates at the room temperature, the mixture is cooled to a temperature lower than 0°C.
Preparation of the hydrochloride of the El + E2 enantiomers
6.4 g of the starting base (content of the E3 + E4 enantiomers: 24%) is dissolved in tetrahydrofuran (45 ml) under boiling. 1 equivalent of 1.25 M hydrogen chloride in ethanol is added to the solution cooled down to 30°C. The mixture is stirred at the room temperature for 2 hours and the separated precipitate is aspirated. After washing with tetrahydrofuran the precipitate is dried.
Yield: 5.0 g (73.3%).
HPLC: 97% content of the El + E2 enantiomers, 1.9% content of the E3 + E4 enantiomers Preparation of the oxalate of the El + E2 enantiomers
220 mg of the starting base (content of the E3 + E4 enantiomers: 17%) is dissolved in tetrahydrofuran (1.5 ml) under boiling. A solution of oxalic acid dihydrate (1 equivalent) in methanol is added to the mixture. The solution is cooled down to -10°C and the separated precipitate is aspirated. After washing with tetrahydrofuran the precipitate is dried.
Yield: 160 g (59%).
HPLC: 95% content of the El + E2 enantiomers, 0.8% content of the E3 + E4 enantiomers.

Claims

Claims
1. A method of isolation of the El and E2 optical isomers, forming an enantiomeric mixture, from a mixture of four optical isomers El, E2} E3, E4, characterized in that the enantiomeric mixture of E3 and E4 is first separated from the solution and subsequently a mixture of El and E2 is isolated in the form of a base in the mother liquors,
wherein El is (lR,2S)-l-(6-bromo-2-memoxyquinolin-3-yl)-4-(dimethylamino)-2- (naphthalen-l-yl)-l-phenylbutan-2-ol, E2 is the (lSs2R)-enantiomer of the same compound, and E3 and E4 are the (1R,2R) and (1S,2S) enantiomers. respectively.
2. The method according to claim 1, characterized in that the mixture of El and E2 in the form of a base is further converted to salts, purified in this form and subsequently converted back to the base.
3. The method according to claim 1 or 2, characterized in that the E3 and E4 isomers are separated from the solution of the four optical isomers in a cyclic ether.
4. The method according to claim 3, characterized in that the cyclic ethers are selected from tetrahydrofuran or 2-memyltetrahydrofuran or a mixture of both the above mentioned cyclic ethers.
5. The method according to claim 4, characterized in that, after addition of a fiirther solvent, solid bases of the El and E2 isomers in a mixture thereof are separated from the mother liquor obtained by separation of the E3 and E4 isomers.
6. The method according to claim 5, characterized in that the further solvent is selected from esters selected from isopropyl acetate, ethyl acetate or from alcohols such as methanol, C6-C8 hydrocarbons, acetonitrile or their mixtures.
7. The method according to claim 6, characterized in that the separation is carried out at a temperature of -15 to +20°C.
8. A method of preparing a salt of the El and E2 isomers according to claim 2, characterized in that the mixture of the El and E2 base is converted to salts in tetrahyc ofuran or 2- memyltetrahydrofuran or in their mixture by addition of an inorganic or organic acid in water or in an organic solvent.
9. The method according to claim 8, characterized in that the inorganic or organic acid are selected from hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, L-tartaric acid, DL-tartaric acid, D-tartaric acid, citric acid and oxalic acid.
10. The method according to claim 9, characterized in that the preparation of the salts of the El and E2 isomers is carried out at a temperature of -15 to +20°C.
11. The method according to any one of claims 8 to 10, characterized in that the base is released from the mixture of the salts of the El and E2 optical isomers with the use of an organic solvent selected from 2-MeTHF, toluene, ethyl methyl ketone, isobutyl methyl ketone, butan-l-ol and a base selected from inorganic carbonates, hydrogen carbonates, hydroxides, phosphates, hydrogen phosphates and dihydrogen phosphates.
12. A salt of formula B*HA, wherein B is a mixture of the El and E2 optical isomers, wherein El is (1 R,2S)- 1 -(6-bromo-2-methoxyquinolin-3 -yl)-4-(dimethylamino)-2-(naphthalen-l -yl)- 1 - phenylbutan-2-ol and E2 is the (lS,2R)-enantiomer of the same compound and HA is an acid selected from HC1, HBr, H2S04, H3P04s L-tartaric, DL-tartaric, D-tartaric, and citric acid.
PCT/CZ2016/000005 2015-01-21 2016-01-13 Method of isolation of a mixture of enantiomers of 1-(6-bromo-2-methoxyquinolin-3-yl)-4-(dimethylamino)-2-(naphthalen-1-yl)-1-phenylbutan-2-ol Ceased WO2016116075A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CZ2015-33 2015-01-21
CZ2015-33A CZ201533A3 (en) 2015-01-21 2015-01-21 Method of isolating mixture of enantiomers

Publications (1)

Publication Number Publication Date
WO2016116075A1 true WO2016116075A1 (en) 2016-07-28

Family

ID=55345617

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CZ2016/000005 Ceased WO2016116075A1 (en) 2015-01-21 2016-01-13 Method of isolation of a mixture of enantiomers of 1-(6-bromo-2-methoxyquinolin-3-yl)-4-(dimethylamino)-2-(naphthalen-1-yl)-1-phenylbutan-2-ol

Country Status (2)

Country Link
CZ (1) CZ201533A3 (en)
WO (1) WO2016116075A1 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004011436A1 (en) 2002-07-25 2004-02-05 Janssen Pharmaceutica N.V. Quinoline derivatives and their use as mycobacterial inhibitors
EP1888604B1 (en) 2005-05-25 2012-03-14 Janssen Pharmaceutica NV Process for preparing (alpha s, beta r)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004011436A1 (en) 2002-07-25 2004-02-05 Janssen Pharmaceutica N.V. Quinoline derivatives and their use as mycobacterial inhibitors
EP1888604B1 (en) 2005-05-25 2012-03-14 Janssen Pharmaceutica NV Process for preparing (alpha s, beta r)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LEE S ET AL: "Handbook of Pharmaceutical Salts: Properties, Selection , and Use, Chapter 8 (Large-Scale Aspects of Salt Formation: Processing of Intermediates and Final Products, Chapter 12 (Monographs on Acids and Bases)", 1 January 2002, HANDBOOK OF PHARMACEUTICAL SALTS : PROPERTIES, SELECTION, AND USE, ZÜRICH : VERL. HELVETICA CHIMICA ACTA ; WEINHEIM [U.A.] : WILEY-VCH, DE, PAGE(S) 191 - 192,211, ISBN: 978-3-906390-26-0, XP002548973 *

Also Published As

Publication number Publication date
CZ201533A3 (en) 2016-08-03

Similar Documents

Publication Publication Date Title
EP3077404B1 (en) Purification of tenofovir alafenamide and its intermediates
JP5503546B2 (en) Separation of 4,5-dimethoxy-1- (methylaminomethyl) -benzocyclobutane
JP6917892B2 (en) Method for producing praziquantel and its precursor
US20100298570A1 (en) Process for the resolution of isoquinoline derivatives
US20100280077A1 (en) Process for Preparation of Stable Amorphous R-Lansoprazole
RU2337096C2 (en) Method of obtaining of glycopyrronium stereoisomer of rr (or ss)-configuration
US8877941B2 (en) Process for the resolution of medetomidine and recovery of the unwanted enantiomer
US7439398B2 (en) Enantiomerically pure atomoxetine and tomoxetine mandelate
JP2002531429A (en) Methods for Tramadol Splitting
US20060020140A1 (en) Process for the preparation of racemic citalopram diol and/or s-or r-citalopram diols and the use of such diols for the preparation o racemic citalopram, r-citalopram and/or s-citalopram
WO2012116752A1 (en) Process of resolution of 1-aminoindan
US8362042B2 (en) Stable R(+)-lansoprazole amine salt and a process for preparing the same
JP4257573B2 (en) Method for producing R (+) α-lipoic acid
WO2016116075A1 (en) Method of isolation of a mixture of enantiomers of 1-(6-bromo-2-methoxyquinolin-3-yl)-4-(dimethylamino)-2-(naphthalen-1-yl)-1-phenylbutan-2-ol
CN102190600A (en) Preparation method of IV intermediate S-diol
EP3230258B1 (en) Process for the preparation of (1s,2r)-milnacipran
WO2012147020A1 (en) An improved process for the preparation of frovatriptan
CN100467457C (en) Method for resolving nefopam
CN109803961B (en) Process for producing (R) -5- (3, 4-difluorophenyl) -5- [ (3-methyl-2-oxopyridin-1 (2H) -yl) methyl ] imidazolidine-2, 4-dione and intermediate for production thereof
WO2016142165A1 (en) Improved process for the optical purification of esomeprazole
JP2002526468A (en) Method for producing (-)-α-difluoromethylornithine monohydrochloride monohydrate
ES2385975T3 (en) Procedure for the preparation of racemic citalopram diol and / or S-O R-citalopram diols and the use of such diols for the preparation of racemic citalopram, R-citalopram and / or S-citalopram
EP3068746A1 (en) Process for the preparation of enatiomerically pure 1-aminoindan
JP2022553028A (en) Industrial method of splitting crocyphos
JP2006526006A (en) Toremifene crystallization method

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16703708

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16703708

Country of ref document: EP

Kind code of ref document: A1